Processa Pharmaceuticals Return on Equity

Processa Pharmaceuticals (PCSA) currently reports a ROE of 4234.62%. That is above the Industrials sector average of 20.56%. Use the charts on this page to explore Processa Pharmaceuticals's ROE history and peer comparisons.

Processa Pharmaceuticals's ROE of 4234.62% is higher than the Industrials sector average of 20.56%. That is roughly 20494.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Processa Pharmaceuticals's current 4234.62% should be judged against Industrials norms (sector average: 20.56%) and against PCSA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 4234.62%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Industrials average is 20.56%. From there, open related valuation or income-statement pages for Processa Pharmaceuticals, and consider following PCSA for alerts when major investors trade the stock.

Processa Pharmaceuticals is classified in the Industrials sector. On ROE, it currently shows 4234.62% versus a sector average near 20.56%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing PCSA with unrelated industries.